TY - JOUR
T1 - Epidemiologic investigation of the relative clearance of haloperidol by mixed-effect modeling using routine clinical pharmacokinetic data in Japanese patients
AU - Yukawa, Eiji
AU - Hokazono, Tsuyoshi
AU - Funakoshi, Akiko
AU - Yukawa, Miho
AU - Ohdo, Shigehiro
AU - Higuchi, Shun
AU - Ichimaru, Ritsuko
AU - Maki, Takako
AU - Matsunaga, Kanemitsu
AU - Anai, Motoaki
AU - Goto, Yoshinobu
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 2000
Y1 - 2000
N2 - The steady-state trough concentrations of haloperidol were studied to clarify the role of the characteristics of Japanese patients in estimating haloperidol dosing regimens by using routine therapeutic drug-monitoring data. Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effect of a variety of developmental and demographic factors on haloperidol clearance values using 270 serum level measurements obtained from 191 patients during their clinical course. The final model describing haloperidol's relative clearance was CL = 0.74 · TBW0.594 · DOSE0.326 · 1.32(CO1) · 0.867(AGE), where CL is clearance (measured in liters per hour), TBW is the total body weight (in kilograms), DOSE is the daily dose of haloperidol (in grams per kilogram per day), CO1 = 1 for concomitant administration of antiepileptic drugs (phenobarbital, phenytoin, or carbamazepine) and CO1 = 0 otherwise, and AGE = 1 for patients aged 55 years or older and AGE = 0 otherwise. Concomitant administration of haloperidol and antiepileptic drugs resulted in a 32% increase in haloperidol clearance. Patients aged 55 years or older showed a 13.3% reduction in clearance values compared with the younger population.
AB - The steady-state trough concentrations of haloperidol were studied to clarify the role of the characteristics of Japanese patients in estimating haloperidol dosing regimens by using routine therapeutic drug-monitoring data. Nonlinear mixed-effects modeling (NONMEM) was used to estimate the effect of a variety of developmental and demographic factors on haloperidol clearance values using 270 serum level measurements obtained from 191 patients during their clinical course. The final model describing haloperidol's relative clearance was CL = 0.74 · TBW0.594 · DOSE0.326 · 1.32(CO1) · 0.867(AGE), where CL is clearance (measured in liters per hour), TBW is the total body weight (in kilograms), DOSE is the daily dose of haloperidol (in grams per kilogram per day), CO1 = 1 for concomitant administration of antiepileptic drugs (phenobarbital, phenytoin, or carbamazepine) and CO1 = 0 otherwise, and AGE = 1 for patients aged 55 years or older and AGE = 0 otherwise. Concomitant administration of haloperidol and antiepileptic drugs resulted in a 32% increase in haloperidol clearance. Patients aged 55 years or older showed a 13.3% reduction in clearance values compared with the younger population.
UR - http://www.scopus.com/inward/record.url?scp=0033713486&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033713486&partnerID=8YFLogxK
U2 - 10.1097/00004714-200012000-00016
DO - 10.1097/00004714-200012000-00016
M3 - Article
C2 - 11106142
AN - SCOPUS:0033713486
SN - 0271-0749
VL - 20
SP - 685
EP - 690
JO - Journal of Clinical Psychopharmacology
JF - Journal of Clinical Psychopharmacology
IS - 6
ER -